RepliCel and Shiseido Complete Collaboration and Technology Transfer Agreement on Technology for Treating Pattern Baldness

RepliCel and Shiseido Complete Collaboration and Technology Transfer Agreement
on Technology for Treating Pattern Baldness

RepliCel Life Sciences Inc. to receive $4.2 million upfront fee, with
additional royalties of $31.5 million from licensing Agreement allowing
Shisedo to use RepliCel's RCH-01 hair regeneration technology treating pattern
baldness in Japan, China, South Korea, Taiwan and the ASEAN countries.

VANCOUVER, BC, July 11, 2013 (GLOBE NEWSWIRE) -- via PRWEB - RepliCel Life
Sciences Inc. (the "Company" or "RepliCel") (OTCBB:REPCF) (CNSX:RP) is pleased
to report that it has completed the previously announced Collaboration and
Technology Development Transfer Agreement (the "Agreement") with Shiseido
Company, Limited ("Shiseido"). A joint steering committee will now be formed
to oversee the transfer of the technology, knowhow and standard operating
procedures. As defined by the Agreement, Shiseido will pay RepliCel an upfront
fee of ¥400,000,000 (approx. CDN $4,200,000). In addition, Shiseido will pay
RepliCel sales milestones amounts of up to ¥3,000,000,000 (approx. CDN
$31,500,000) and royalties.

The Agreement gives Shiseido an exclusive geographic license to use RepliCel's
RCH-01 hair regeneration technology in Japan, China, South Korea, Taiwan and
the ASEAN countries representing a population of approximately 2.1 billion
people. Shiseido and RepliCel will collaborate on the continued improvement of
the technology and will conduct human clinical trials in each of their
territories with the goal of commercializing a safe and effective hair
regenerative treatment to help those suffering from pattern baldness and
thinning hair.

David Hall, CEO of RepliCel commented, "This agreement gives RepliCel's RCH-01
hair regeneration technology important third-party validation from one of the
most respected cosmetic companies in the world. In addition, the Japanese
government has recently committed to establish a new approval process for
regenerative medicine products focused on accelerating approval timelines.
This changing regulatory environment enhances the strategic nature of our
collaboration with Shiseido. In parallel with RepliCel's planned Phase II
trial in Europe, the Shiseido license represents a second clinical pathway for
the development of our RCH-01 technology."

"We look forward to working with Shiseido with its deep expertise in hair
research. We anticipate that our collaborative efforts will support the
continued improvement of our technology," stated Dr. Rolf Hoffmann, Chief
Medical Officer of RepliCel. "This license represents the first of many
development and collaboration agreements we intend to undertake around our
broader platform of addressing cellular deficits in diseases such as pattern
baldness and tendinosis," concluded Dr. Hoffmann.

Asia's Hair Loss Market

With the increasing awareness of baldness as a medical condition that can be
treated; the demand for hair loss treatments has sharply risen; especially in
the Asian market. For example, a study by the Peking University People's
Hospital published in the British Journal of Dermatology in 2010 found that 21
percent of adult males and six percent of females in China suffer from
hormone-driven hair loss. Furthermore, the International Society of Hair
Restoration Surgery's (ISHRS) biennial survey of hair restoration physicians
found that the number of hair restoration patients in Asia grew 345% from 2004
to 2010. Shiseido has also conducted research on hair and scalp concerns.
Their survey of women living in Tokyo, Shanghai, Chengdu and Bangkok found
that women aged 40+ commented that their hair was thinning.

RCH-01 Procedure

RCH-01 is a patented cellular replication and implantation technology designed
to rejuvenate damaged and miniaturized hair follicles in balding scalp. This
technology has been developed over ten years of research, experimentation and
clinical trials. The mechanics of this technology involve the extraction of as
few as 20 hair follicles from the back of a patient's scalp where healthy
cycling hair follicles reside. Specific cells are isolated from hair follicles
and are cultured in a current Good Manufacturing Practice compliant facility
using the Company's proprietary cellular replication process. The cultured
cells are reintroduced back into balding areas on a patient's scalp and are
expected to rejuvenate damaged hair follicles leading to the growth of new
healthy hair fibers.

About RepliCel Life Sciences

The Company is developing two autologous cell therapies; the first being a
cellular treatment for androgenetic alopecia (pattern baldness); RCH-01; and
the other being a cell therapy for the treatment of chronic tendon injuries
(RCT-01). Both products are based on RepliCel's innovative technology which
utilizes cells isolated from a patient's own healthy hair follicles to address
specific cellular deficits. Each program is in the regulatory process of
preparing for Phase II clinical trials. RepliCel's business model is to
develop and license its technologies to fully integrated life science

About Shiseido Company, Limited

Shiseido was established in 1872 as Japan's first Western-style pharmacy.
Since then, the company has led the cosmetic technology and culture in Japan
over more than 100 years. The company now aspires to become a "global player
to represent Asia with origins in Japan" and operate businesses all over the
world, including Europe, the U.S. and Asia. Its representative global brand,
"SHISEIDO" is now sold in 89 countries and regions as of April 2013.

Notice Regarding Forward Looking Statements

This press release contains projections and forward-looking statements, as
that term is defined under applicable securities laws. Statements in this
press release, which are not purely historical, are forward-looking statements
and include the following: (i) that the Company will conduct further human
clinical trials; (ii) that ongoing research collaboration will be conducted by
the Company and Shiseido for the continued improvement of the technology;
(iii) that a commercial, safe and effective hair regenerative treatment will
be developed and commercialized; (iv) that the Company and Shiseido will
develop further improvements to the technology; (v) that the Company will
undertake and enter into development and collaboration agreements for the
development of its technologies; and (vi) and that the Company's technology
will rejuvenate damaged hair follicles leading to the growth of new healthy
hair fibers. These statements are only predictions and involve known and
unknown risks which may cause actual results and the Company's plans and
objectives to differ materially from those expressed in the forward-looking
information, including: that negative results from the Company's clinical
trials may impact further clinical trials, development, approval and
commercialization of the technology; the effects of government regulation on
the Company's business, including the future development of the technology;
risks associated with the Company's ability to obtain and protect rights to
its intellectual property; risks and uncertainties associated with the
Company's ability to raise additional capital; that the Company may not be
able to find other parties will to participate in the development and
collaboration of its technologies, and other factors beyond the Company's
control. Although the Company believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot guarantee future results,
levels of activity or performance. Further, any forward-looking statement
speaks only as of the date on which such statement is made, and, except as
required by applicable law, the Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after the date on
which such statement is made or to reflect the occurrence of unanticipated
events. New factors emerge from time to time, and it is not possible for
management to predict all of such factors and to assess in advance the impact
of such factors on the Company's business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from
those contained in any forward-looking statement. Readers should consult all
of the information set forth herein and should also refer to the risk factor
disclosure outlined in the Company's annual report on Form 20-F for the fiscal
year ended December 31, 2012 and other periodic reports filed from
time-to-time with the Securities and Exchange Commission on Edgar at and with the British Columbia Securities Commission on

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit

CONTACT: RepliCel Life Sciences Inc.
         Tammey George
Press spacebar to pause and continue. Press esc to stop.